Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialAndrew McGarry, Karl Kieburtz, Dennis To et al.|The Lancet Neurology|2023Cited by 128
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease familiesLianna Ishihara, Fayçal Hentati, Rachel A. Gibson et al.|Movement Disorders|2006Cited by 92